FRI0692 Anti-tnf treatments for women with chronic inflammatory diseases: comparing attitudes and perceptions of physicians in europe and the us
Authors: A. Tincani, P. Taylor, R. Fischer-Betz, C. Ecoffet, E. Chakravarty
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> For Women of Childbearing Age (WoCBA) with chronic inflammatory diseases (CID), onset, diagnosis and treatment initiation often overlap with peak reproductive years. High disease activity is associated with increased risk of pregnancy complications and adverse outcomes, and achieving disease control in these patients (pts) is therefore an important goal. Tumour necrosis factor antagonists (anti-TNFs) are effective treatments, but few data are available on how physicians utilise them in clinical practice for this specific pt group. <h3>Objectives:</h3> To help better understand physicians' perceptions and attitudes towards treating WoCBA pts with anti-TNFs during pregnancy and lactation, and gain insights into differences between Europe- and US-based physicians. <h3>Methods:</h3> The survey was conducted online in the US in July 2017, and in EU5 (France, Italy, Spain, UK and Germany) in Nov/Dec 2017, through SERMO RealTime. WoCBA were defined as female pts aged 18–45. Participants included rheumatologists (RH), gastroenterologists (GI), dermatologists (DM) and obstetricians/gynaecologists (OB). Here, we present data for RH and OB. <h3>Results:</h3> 203 healthcare professionals (HCPs) from the US participated, of whom 50 were RH and 50 OB; 401 HCPs from EU5 participated, of whom 152 were RH and 114 OB; over half of the female pt population with CID among the prescribing specialists were WoCBA. Overall, EU5 HCPs were less inclined to prescribe anti-TNF treatments for WoCBA pts; compared to the other specialists, US RH (43%) had the highest proportion of WoCBA pts prescribed anti-TNFs (EU5 RH: 33%; EU DM: 24%; US DM: 27%; US GI: 31%). However, HCPs' comfort with prescribing anti-TNF treatments consistently declined in both US and EU5 with onset of family planning (figure 1<b>A</b>). EU5 RH (61%) and OB (67%) were more likely to recommend discontinuation of anti-TNFs before conception than US HCPs (RH: 46%; OB: 62%); similarly, &gt;50% EU5 RH and OB agreed that women should stop anti-TNFs post-conception (US RH: 34%; OB: 54%). These findings may be explained by the fact that more US HCPs strongly agreed on making disease control during pregnancy their priority (US RH: 42% vs EU5 RH: 25%) and that controlled disease reduces risk of pregnancy complications (US RH: 42% vs EU5 RH: 28%), as well as the observation that more EU5 RH (34%) than US (12%) were very concerned about adverse events, including infection or poor birth outcomes, in pregnant pts taking anti-TNFs. More EU5 than US RH strongly believed breastfeeding pts should not take anti-TNFs, although a high degree of uncertainty was indicated (figure 1<b>B</b>). <h3>Conclusions:</h3> Our survey demonstrates the variability in confidence in clinical management of women with CID and highlights differences in physicians' attitudes between RH vs OB and EU vs US. Uncertainty and concerns about risks of anti-TNF use during pregnancy and breastfeeding are common, emphasising the need for better information and education of HCPs, especially in Europe, regarding the appropriate use of anti-TNFs during pregnancy and breastfeeding. <h3>Acknowledgements:</h3> This study was funded by UCB Pharma, conducted by SERMO, with editorial services by Costello Medical. We thank the physicians who contributed. <h3>Disclosure of Interest:</h3> A. Tincani Grant/research support from: AbbVie, Actelion, Pfizer, UCB Pharma, Consultant for: Celgene, Pfizer, P. Taylor Grant/research support from: UCB Pharma, Janssen, Galapagos, Eli Lilly, Abide Therapeutics, Consultant for: Novartis, AbbVie, Eli Lilly, UCB Pharma, Pfizer, Biogen, Janssen, Sanofi, GSK, R. Fischer-Betz Consultant for: AbbVie, BMS, Celgene, Chugai, Novartis, Lilly, UCB Pharma, Pfizer, Janssen, Sanofi, C. Ecoffet Employee of: UCB Pharma, E. Chakravarty Grant/research support from: UCB Pharma